Trulieve Cannabis (TRLV) EBITDA (2020 - 2026)

Trulieve Cannabis (TRLV) has reported EBITDA for 7 consecutive years, with $35.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 7.2% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $145.9 million (up 71.63% YoY), while the FY2025 annual figure was $168.7 million, up 13.05% from the prior year.
• EBITDA came in at $35.7 million for Q1 2026 at Trulieve Cannabis, up from $15.3 million in the prior quarter.
• The five-year high for EBITDA was $61.6 million in Q2 2022, with the low at -$291.3 million in Q2 2023.
• Average EBITDA over 5 years is $11.1 million, with a median of $35.7 million recorded in 2026.
• Across the five-year window, EBITDA tumbled 573.07% in 2023 and surged 6734.63% in 2025, its largest moves.
• Year by year, EBITDA stood at -$2.0 million in 2022, then jumped by 1459.19% to $27.3 million in 2023, then plunged by 95.21% to $1.3 million in 2024, then soared by 1069.5% to $15.3 million in 2025, then soared by 133.54% to $35.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $35.7 million, $15.3 million, and $42.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.